Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.85 Million USD | 21.21% |
| 2023 | 3.17 Million USD | 2.33% |
| 2022 | 3.1 Million USD | 0.8% |
| 2021 | 3.08 Million USD | -17.63% |
| 2020 | 3.73 Million USD | -15.06% |
| 2019 | 4.4 Million USD | -35.47% |
| 2018 | 6.82 Million USD | 23.24% |
| 2017 | 5.53 Million USD | 88.04% |
| 2016 | 2.94 Million USD | -20.0% |
| 2015 | 3.68 Million USD | 141.82% |
| 2014 | 1.52 Million USD | 91.64% |
| 2013 | 794.22 Thousand USD | 35.95% |
| 2012 | 584.18 Thousand USD | 90.38% |
| 2011 | 306.84 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.16 Million USD | -0.25% |
| 2024 Q3 | 3.73 Million USD | -1.8% |
| 2024 Q4 | 3.85 Million USD | 3.07% |
| 2024 Q2 | 3.8 Million USD | 20.06% |
| 2023 Q3 | 3.08 Million USD | 2.04% |
| 2023 Q1 | 2.86 Million USD | -7.84% |
| 2023 FY | 3.17 Million USD | 2.33% |
| 2023 Q2 | 3.02 Million USD | 5.65% |
| 2023 Q4 | 3.17 Million USD | 2.99% |
| 2022 Q1 | 2.36 Million USD | -23.11% |
| 2022 FY | 3.1 Million USD | 0.8% |
| 2022 Q4 | 3.1 Million USD | -0.37% |
| 2022 Q3 | 3.11 Million USD | 2.52% |
| 2022 Q2 | 3.04 Million USD | 28.35% |
| 2021 Q2 | 3.64 Million USD | 10.13% |
| 2021 Q1 | 3.31 Million USD | -11.42% |
| 2021 FY | 3.08 Million USD | -17.63% |
| 2021 Q4 | 3.08 Million USD | 1.61% |
| 2021 Q3 | 3.03 Million USD | -16.91% |
| 2020 Q1 | 4.73 Million USD | 7.64% |
| 2020 Q2 | 5.73 Million USD | 21.06% |
| 2020 Q3 | 4.91 Million USD | -14.41% |
| 2020 FY | 3.73 Million USD | -15.06% |
| 2020 Q4 | 3.73 Million USD | -23.84% |
| 2019 FY | 4.4 Million USD | -35.47% |
| 2019 Q3 | 3.67 Million USD | -20.44% |
| 2019 Q2 | 4.61 Million USD | -18.16% |
| 2019 Q1 | 5.64 Million USD | -17.33% |
| 2019 Q4 | 4.4 Million USD | 19.87% |
| 2018 FY | 6.82 Million USD | 23.24% |
| 2018 Q3 | 6.88 Million USD | -5.42% |
| 2018 Q2 | 7.27 Million USD | 5.48% |
| 2018 Q1 | 6.9 Million USD | 24.62% |
| 2018 Q4 | 6.82 Million USD | -0.88% |
| 2017 Q1 | 1.98 Million USD | -32.57% |
| 2017 Q2 | 3.97 Million USD | 100.29% |
| 2017 Q3 | 4.75 Million USD | 19.69% |
| 2017 Q4 | 5.53 Million USD | 16.33% |
| 2017 FY | 5.53 Million USD | 88.04% |
| 2016 Q1 | 3.48 Million USD | -5.25% |
| 2016 FY | 2.94 Million USD | -20.0% |
| 2016 Q4 | 2.94 Million USD | -42.76% |
| 2016 Q3 | 5.14 Million USD | 5.76% |
| 2016 Q2 | 4.86 Million USD | 39.47% |
| 2015 Q1 | 1.83 Million USD | 20.62% |
| 2015 FY | 3.68 Million USD | 141.82% |
| 2015 Q2 | 1.93 Million USD | 5.13% |
| 2015 Q4 | 3.68 Million USD | 70.35% |
| 2015 Q3 | 2.16 Million USD | 11.94% |
| 2014 Q1 | 1.25 Million USD | 58.28% |
| 2014 FY | 1.52 Million USD | 91.64% |
| 2014 Q4 | 1.52 Million USD | 30.62% |
| 2014 Q3 | 1.16 Million USD | 9.69% |
| 2014 Q2 | 1.06 Million USD | -15.49% |
| 2013 Q4 | 794.22 Thousand USD | 5.62% |
| 2013 FY | 794.22 Thousand USD | 35.95% |
| 2013 Q3 | 751.97 Thousand USD | 14.71% |
| 2013 Q2 | 655.52 Thousand USD | 2.95% |
| 2013 Q1 | 636.72 Thousand USD | 8.99% |
| 2012 Q3 | 482.22 Thousand USD | 36.12% |
| 2012 Q4 | 584.18 Thousand USD | 21.14% |
| 2012 FY | 584.18 Thousand USD | 90.38% |
| 2012 Q2 | 354.27 Thousand USD | 0.0% |
| 2011 Q4 | 306.84 Thousand USD | 0.0% |
| 2011 FY | 306.84 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13939.383% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 59.313% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.686% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -376.193% |
| Rebus Holdings, Inc. | 5.24 Million USD | 26.528% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.474% |
| Qrons Inc. | 1.48 Million USD | -158.708% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -214.091% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.859% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8516.932% |
| Skye Bioscience, Inc. | 14.07 Million USD | 72.631% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.775% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 59.806% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -813.595% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.303% |
| Intellipharmaceutics International Inc. | 12 Million USD | 67.928% |
| Mesoblast Limited | 188.44 Million USD | 97.956% |
| Marizyme, Inc. | 26.67 Million USD | 85.562% |
| Genus plc | 485 Million USD | 99.206% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 34.081% |
| Pharming Group N.V. | 244.07 Million USD | 98.422% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -91.601% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -53.057% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1.353% |
| ContraFect Corporation | 32.53 Million USD | 88.161% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -94.388% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -0.621% |
| IMV Inc. | 37.93 Million USD | 89.847% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 67.3% |
| MultiCell Technologies, Inc. | 1617.67 USD | -237984.653% |
| ONE Bio Corp. | 27.49 Million USD | 85.993% |
| Accustem Sciences Inc. | 1.07 Million USD | -256.865% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.025% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -82.094% |
| Q BioMed Inc. | 8.13 Million USD | 52.644% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.356% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 25.157% |
| Biomind Labs Inc. | 1.49 Million USD | -156.999% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.756% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 57.406% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 79.072% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -168.605% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2610.457% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1815.026% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 32.97% |
| GB Sciences, Inc. | 5.41 Million USD | 28.908% |
| Alpha Cognition Inc. | 7.16 Million USD | 46.245% |
| HST Global, Inc. | 593.59 Thousand USD | -548.832% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -205.864% |
| Halberd Corporation | 728.71 Thousand USD | -428.52% |
| Enzolytics Inc. | 365.26 Million USD | 98.946% |
| Agentix Corp. | 2.51 Million USD | -53.409% |
| Resverlogix Corp. | 67.39 Million USD | 94.285% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -359.196% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.134% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -124.704% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 84.436% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 67.644% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -5.082% |
| AVAX Technologies, Inc. | 3.99 Million USD | 3.564% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13870.126% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.71% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1513.811% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3.136% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -465.692% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -42.033% |
| Kadimastem Ltd | 3.5 Million USD | -9.888% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5654.492% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.338% |
| BioStem Technologies, Inc. | 15.9 Million USD | 75.784% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -728.8% |
| LadRx Corporation | 2.2 Million USD | -75.023% |
| Cell Source, Inc. | 15.8 Million USD | 75.634% |
| Regen BioPharma, Inc. | 5.45 Million USD | 29.43% |
| Regen BioPharma, Inc. | 5.45 Million USD | 29.43% |
| NovAccess Global Inc. | 7.86 Million USD | 51.004% |
| Affymax, Inc. | 8.87 Million USD | 56.584% |
| Itoco Inc. | 1.65 Million USD | -132.975% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -87.731% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 36.33% |
| Mobile Lads Corp. | 1.31 Million USD | -193.219% |
| CytoDyn Inc. | 127.89 Million USD | 96.989% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9114.153% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -145.881% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 65.131% |
| SYBLEU INC | 681.41 Thousand USD | -465.211% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 36.882% |
| International Stem Cell Corporation | 5.27 Million USD | 27.015% |
| Bioxytran, Inc. | 3.24 Million USD | -18.524% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -515.431% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 16.584% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.605% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 82.702% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -90.157% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 29.693% |
| Neutra Corp. | 973.52 Thousand USD | -295.615% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 86.726% |
| PureTech Health plc | 125.58 Million USD | 96.933% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -2.51% |
| IXICO plc | 1.9 Million USD | -102.675% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 81.239% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.272% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Cellectis S.A. | 249.36 Million USD | 98.456% |